Коррекция метаболических нарушений у больных ишемической болезнью сердца на фоне метаболического синдрома
Наталия Ивановна Винник, Елена Николаевна Пронина, Светлана Ивановна Данильченко et al. · Universum · 2013
The purpose of the research was the investigation of the influence of pioglitazone on the indices of systemic inflammation and insulin-resistance in patients with ischemic heart disease (IHD) in combination with the metabolic syndrome (MS). It was registered that in patients with IHD in combination with MS the level of ceruloplasmin, C-reactive protein, tumor necrosis factor-α, Cpeptide, antigenically responsive insulin and glucose in blood, NOMA-index was increased. As a result of traditional antianginal therapy of patients with IHD in combination with MS, which were prescribe to take pioglitazone 30 mg once a day during a 3-month period, a decrease of systemic chronic inflammation and indices of insulin-resistance was reliably evident. This allows recommending the inclusion of pioglitazone in complex therapy of patients with ischemic heart disease in combination with metabolic syndrome.
Cited by 0 works.
Authors
- Наталия Ивановна Винник
- Елена Николаевна Пронина
- Светлана Ивановна Данильченко
- Александр Юрьевич Половик
- L.K. Voskresenska
- Ангелина Валериевна Пирог-Заказникова
- Наталия Ивановна Винник
- Elena A. Pronina
- Sergei N. Danilchenko
- Олександр Юрійович Половик
- L.K. Voskresenska
- A. V. Pyrog-Zakaznikova
- Наталія Іванівна Винник
- Олена Миколаївна Проніна
- Світлана Іванівна Данильченко
- Олександр Юрійович Половик
- Людмила Костянтинівна Воскресенська
- А. В. Пирог-Заказникова